DISTRIBUTION OF MOLECULAR SUBTYPES OF ADVANCED LUNG ADENOCARCINOMA AND CLINICAL OUTCOMES IN A CENTER OF ARGENTINA

GONZALO RECONDO JR1, VALERIA DENNINGHOFF2*, MARÍA T. CUELLO2, CONSTANZA LORENTE2, MARTÍN GRECO1, MÁXIMO DE LA VEGA1, ALEJANDRA AVAGNINA2, GONZALO RECONDO1*

1Medical Oncology, Department of Internal Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC)
2Department of Pathology, Centro de Educación Médica e Investigaciones Clínicas (CEMIC)
*Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
Gonzalo Recondo Jr and Valeria Denninghoff have contributed equally to the manuscript

Abstract
The prevalence of relevant oncogenic drivers in lung adenocarcinoma varies in our region and data on clinical outcomes is scarce. The objective of the study was to describe the prevalence of KRAS, BRAF and EGFR mutations and ALK translocations in patients with advanced lung adenocarcinoma, and to depict the clinical outcome according to treatment strategies. Patients with adequate tumor biopsy sampling were included. KRAS, BRAF and EGFR mutations were studied by Sanger sequencing. ALK translocations were studied by fluorescent in situ hybridization (FISH) and immunohistochemistry (IH) with antibodies against ALK with clones D5F3 and 5A4. Informed consent was signed by 118 patients and 84 (72%) with complete molecular analysis were included. KRAS mutations were detected in 16 samples (19%), EGFR in 11 (13%), 9 of them conferring sensitivity to EGFR inhibitors, and BRAF mutations in 1 (1%). ALK translocations were detected in 3 samples (4%). Median follow-up was 42.4 [interquartile range (IQR): 27.0-64.2] months. Globally, median overall survival was 10.3 [IQR: 5.6-20.2] months. Median survival was 10.8 [IQR: 6.0-20.3] months in the group of patients without detectable molecular alteration, 9.6 [IQR: 3.7-16.1] months in KRAS mutant population (HR: 1.08; p = 0.82) and 32.5 [IQR: 19.6-38.4] months in patients with ALK translocations or sensitizing EGFR mutated tumors treated with tyrosine kinase inhibitors (HR: 0.27; p = 0.03). In conclusion, the prevalence of molecular alterations and outcomes in our population is similar to that reported in other studies in Western countries.

Key words: lung cancer, molecular subtypes, survival

Resumen
Distribución de subtipos moleculares de adenocarcinoma de pulmón y resultados clínicos en un centro de Argentina. La prevalencia de alteraciones en oncogenes en adenocarcinoma de pulmón varía en nuestra región. El objetivo fue describir la prevalencia de mutaciones en KRAS, BRAF y EGFR y las translocaciones de ALK en pacientes con adenocarcinoma de pulmón y estudiar la supervivencia de acuerdo a subtipos moleculares. Se incluyeron pacientes con biopsias adecuadas para el estudio. Se evaluó el estado mutacional de KRAS, BRAF y EGFR por secuenciación con la técnica de Sanger. Las translocaciones de ALK se estudiaron por hibridación in situ por fluorescencia (FISH) e inmunohistoquímica (IHQ) contra ALK (clones D5F3 y 5A4). De 118 pacientes evaluados, se incluyeron 84 (72%) con análisis molecular completo. Se detectaron mutaciones de KRAS en 16 muestras (19%), EGFR en 11 (13%), y BRAF en 1 muestra (1%). Se detectaron rearrreglos de ALK en 3 muestras (4%). La mediana de seguimiento de los pacientes fue de 42.4 [rango intercuartílico (RIC): 27.0-64.2] meses. Globalmente, la mediana de supervivencia en la población fue 10.3 [RIC: 5.6-20.2] meses y fue de 10.8 [RIC: 6.0 20.3] meses en pacientes con alteraciones moleculares detectables. La mediana de supervivencia de los pacientes con mutación en KRAS fue de 9.6 [RIC: 3.7-16.1] meses (HR: 1.08; p = 0.82) y 32.5 [RIC: 19.6-38.4] meses en el grupo con rearrreglos de ALK o mutaciones en EGFR tratados con inhibidores de tirosina quinasa (HR: 0.27; p = 0.03). En conclusión, la prevalencia de alteraciones moleculares en nuestra población fue similar a otros países occidentales.

Palabras clave: cáncer de pulmón, subtipos moleculares, supervivencia
Lung cancer is the first cause of cancer-related deaths in the world. In Argentina, by the year 2018, lung cancer accounted for 10,662 estimated deaths, being the first in cancer mortality among men \(^1\). Mortality has been increasing among females and decreasing among males in the last decade. Worldwide, only 15% of patients remain alive at 5 years, mainly because around 70% of lung cancers present at advanced stages. Non-small cell lung cancer (NSCLC) accounts for 85% of cases, with lung adenocarcinoma being the most common histology \(^2\).

For decades, chemotherapy was the sole treatment for metastatic lung adenocarcinoma until the development of targeted therapies against driver oncogenes and the emerging role of immunotherapy. Over 60% of lung adenocarcinomas harbor a genomic mutation, amplification or translocation in key cell signaling pathways \(^3,5\). Many of them can be targeted with actionable drugs \(^6\). The V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations accounted for 32% of cases in The Cancer Genome Atlas (TCGA), with no effective therapy against this mutation \(^5\). The epidermal growth factor receptor mutations (EGFR) occur in 11% to 15% in Western countries, and sensitizing mutations predict responses with EGFR inhibitors in around 70% of patients \(^10-15\). Erlotinib, gefitinib and afatinib are approved EGFR tyrosine kinase inhibitors (TKI) currently available for first line therapy in the metastatic setting. Osimertinib is a third generation EGFR inhibitor with proven efficacy in reverting treatment resistance when the T790M secondary mutation is present \(^16\).

Anaplastic lymphoma kinase (ALK) rearrangements occur in 3% to 5% of lung adenocarcinomas and confer sensitivity to ALK inhibitors like crizotinib, ceritinib, alectinib, brigatinib and lorlatinib \(^5,9,17-21\). As for EGFR inhibitors, second and third generation ALK inhibitors can potentially revert acquired resistance and have enhanced central nervous system penetration \(^22,23\). Dabrafenib and trametinib, BRAF and MEK inhibitors respectively, have shown activity in patients with BRAF V600E mutant lung cancers \(^24\).

The distributions of these molecular alterations vary according to race and, consequently, geographical localization. Approximately 30-50% of Asian patients with lung adenocarcinoma harbor EGFR mutations compared to 11% in the Caucasian population \(^25\). There are no significant differences in ALK rearrangements between Asian and Caucasian populations \(^26\).

In Latin America, the largest analysis of 5738 lung cancer patients reported variable results in the prevalence of EGFR mutations ranging from 14% in Argentina, 25% in Colombia, 27% in Panama, 31% in Costa Rica, 34% in Mexico to 51% in Peru \(^27\). The largest series in Brazil shows a 25% to 30% prevalence of EGFR mutations \(^28,29\). The frequency of KRAS mutations in Latin-American population is around 14%, as evidenced by data from México, Colombia and Peru, and Brazil \(^27,28\). There are no data available on the prevalence of KRAS and BRAF mutations in lung cancer in Argentina.

This study reports the prevalence of somatic mutations in EGFR, KRAS, BRAF and ALK translocation in consecutive patients with advanced stage lung adenocarcinoma in a prospective population at a single institution in Argentina. The treatments and survival of the patients in this cohort are also described.

**Materials and methods**

Consecutive patients with newly diagnosed stage IIIB or IV lung adenocarcinoma or disease relapse after surgery were eligible to participate in the study. Eligible patients were over 18 years of age, had an Eastern Cooperative Group (ECOG) performance status ranging from 0 to 2, and tissue sample available for complete molecular analysis. Patients were excluded from the study in the case of inadequate tissue sample for complete analysis or different histopathological diagnosis on biopsy revision.

This is a descriptive prospective study carried out at a single academic institution in the city of Buenos Aires. Patients were enrolled from March 2012 to December 2014 and were followed until their death, withdrawal of informed consent or study cut-off on February 20\(^{th}\), 2016. The primary endpoint of the study was to determine the prevalence of mutations in EGFR, KRAS and BRAF, as well as ALK translocations. The secondary endpoints were to describe patient’s characteristics, treatment strategies and clinical outcomes according to the tumor molecular subtype and compare the yield of surgical and non-surgical biopsies (endoscopic or percutaneous image-guided) for complete molecular analysis. The attending physician selected patient treatments based on molecular biology status and the standard treatments approved in Argentina.

The protocol was reviewed and approved by the institution ethics committee and was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice protocol requirements. All patients signed an informed consent form to participate in the study.

Histopathology diagnosis: formalin-fixed paraffin-embedded tissue (FFPET) samples were cut in 3-4µm sections and stained with hematoxylin and eosin for morphological analysis. Additional complementary immunohistochemistry assays were performed when necessary for diagnostic purposes, and tumor histology was defined by the World Health Organization (WHO) classification of lung cancer \(^37\). All samples were reviewed to confirm adenocarcinoma histology.

Molecular biology: DNA was purified from FFPET samples with a minimum of 70% of tumor cells selected by tissue microdissection. Paraffin was removed with xilol-ethanol 100% and DNA was purified with QIAamp® DNA FFPEt (Qiagen, Germany). Purity and yield were measured with spectrophotometry. PCR amplification was performed with intronic primers.
for KRAS exon 2, EGFR exons 18 to 21 and BRAF exons 11 and 15 (Table 1). All PCR products were evaluated by electrophoresis with agarose gel 2% in TBE 1X solution with ethidium bromide, and were analyzed under UV light. Sanger sequencing was done with BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, USA). The sequences were separated by capillary electrophoresis in ABI PRISM 310 Genetic analyzer (Applied Biosystem, Foster City, CA, USA).

ALK determination was done by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH): ALK fusions were tested by FISH with Vysis ALK Break Apart Probe kit (2p23/ALK translocation detection, Abbott, USA), IHC with ALK Testing (clone D5F3, Ventana-Roche, CE-IVD) and manual IHC with monoclonal antibody 5A4 (ab17127, ABCAM-Inc. Cambridge, MA, USA).

FFPE FISH tissue samples were processed in 4-5 micron sections. Enzymatic digestion was performed with Vysis Paraffin Pretreatment IV. The Food and Drug Administration (FDA) approved Vysis ALK Break Apart Probe kit (2p23/ALK translocation detection, Abbott, USA), IHC with ALK Testing (clone D5F3, Ventana-Roche, CE-IVD) and manual IHC with monoclonal antibody 5A4 (ab17127, ABCAM-Inc. Cambridge, MA, USA).

For descriptive statistics, variables were grouped and categorized as continued or categorical. Continuous variables were summarized with median (p50) and interquartile range (p25-p75). Categorical variables were presented as proportions. Overall survival was calculated from the time of diagnosis of stage IIIB or metastatic disease until death or study termination. Survival analyses were estimated with Kaplan-Meier, and the comparison between groups was evaluated with Wilcoxon rank-sum (Mann-Whitney) test. Median follow-up time was estimated with the reverse Kaplan-Meier method. The yield of surgical and non-surgical (endoscopic or percutaneous) biopsies for molecular analysis was assessed by comparing the proportion of complete, incomplete and absence of molecular analysis between procedure types using the Fisher exact test.

Results

From March 2012 to December 2014, 118 consecutive patients signed the informed consent. Two individuals with an alternative diagnosis on pathology revision were excluded from the study, one with diagnosis of pleural mesothelioma and one with squamous NSCLC. From 116 individuals with lung adenocarcinoma histology, 32 (28%) had tumor biopsies with inadequate or insufficient tissue for complete analysis: 21 had incomplete molecular/
IHC profiling and 11 samples were not suitable for any molecular/IHC technique. Therefore, 84 individuals (72%) with complete molecular profiling in the tumor sample were included in the analysis. (Fig. 1)

Lung biopsies were the most frequently studied (n = 63), followed by lymph nodes (n = 25), bone (n = 13), brain (n = 7), liver (n = 4), adrenal gland (n = 2), kidney (n = 1) and soft tissue metastasis (n = 1). From 116 biopsies with diagnosis of lung adenocarcinomas evaluated for IHC/molecular analysis, 71 (61.2%) were surgical biopsies, 34 (29.3%) were percutaneous image-guided biopsies and 11 (9.5%) were endoscopic biopsies. The yield of surgical biopsies for complete molecular analysis was significantly higher compared to non-surgical biopsies, 87% versus 49% (p = 0.0001). Around 20% of non-surgical biopsies were not suitable for molecular analysis compared to 3% of surgical biopsies (Fig. 2).

The median age for patients with complete molecular analysis was 64 years [IQR: 58-71] and 55% were men. A total of 54 patients (64%) presented with upfront metastatic disease and 30 (36%) had disease relapse after initial curative intent: stage I (n = 15), stage II (n = 8), and stage III disease (n = 7). With regard to smoking habits, 40 patients (48%) were former smokers, 28 (33%) were current smokers and 16 (19%) were never smokers. ECOG performance status score was 0 or 1 in 84% of individuals and 18% had experienced greater than 10% of weight loss at diagnosis. The most common sites of metastasis were the bones, lymph nodes, lungs and central nervous system (Table 2).

A genetic alteration was reported in 37% of analyzed tumor samples: KRAS mutations were detected in 16 samples (19%), EGFR mutations in 11 samples (13%), ALK rearrangements in 3 samples (4%) and a BRAF mutation in 1 sample (1%). No molecular alterations were detected in 52 samples (53%) (Fig. 3).

The following mutations were detected in KRAS: G12C (n = 5), G12D (n = 3), G12V (n = 3), G13S (n = 3), G13B (n = 2) and G13C (n = 1). One sample harbored a KRAS G12C and G13S co-mutation. In samples with EGFR mutations, 9 had mutations predicting benefit to treatment with EGFR TKI: exon 19 deletions (n = 5), L858R in exon 21 (n = 3), E709K in exon 18 (n = 1). Two samples harbored exon 20 insertions (D770_N771 and V774_C775), associated with primary resistance to treatment with EGFR TKI.

ALK rearrangement were detected by FISH and ALK IHC with clone D5F3 in 3 samples (4%). We observed an IHC false negative result in one case with clone 5A4 (score 1+). One sample (1%) had a BRAF G469A mutation in exon 11. This mutation is associated with lack of response to BRAF inhibitors. We did not detect BRAF V600E mutations.
Globally, 71 patients (84%) received at least one line of systemic therapy for advanced disease: 43 (51%) received one, 18 (21%) two lines, 8 (10%) three lines and 2 (2%) received 4 lines of therapy. Carboplatin or cisplatin plus pemetrexed was the preferred first line regimen (77%). Other first line treatments were platinum-based combinations of paclitaxel or pemetrexed with bevacizumab (8%), and carboplatin given concomitantly with taxanes (6%).

In patients with non-detectable alterations (n = 53) and KRAS mutant tumors (n = 16), 46 (87%) and 15 (94%) received chemotherapy, respectively. Seven patients did not receive chemotherapy treatment because of clinical deterioration and poor performance status. In the group of patients with EGFR mutations (n = 11), three did not meet clinical criteria for treatment with TKI due to the presence of EGFR TKI resistant exon 20 insertions (n = 2) and surgical resection of a single brain metastasis in a patient without evidence of extracranial disease (n = 1). Among 8 patients with clinical indication of treatment with EGFR TKI, 3 received treatment with erlotinib, one with gefitinib and one with afatinib. Among patients with ALK translocation, one received ALK TKI crizotinib and the remaining received chemotherapy. Reasons for not receiving EGFR/ALK inhibitors were: rapid clinical deterioration (n = 3), lack of access to TKI by insurance delay (n = 1) and false negative testing with ALK 5A4 antibody (n = 1).

At study completion, 71 patients had died (85%). Median overall survival for the whole population (n = 84) was 10.3 months [IQR: 5.6-20.2]. In the group of patients with tumors that did not have detectable molecular alterations, median overall survival was 10.8 months [IQR: 6.0-20.3]. Patients with KRAS mutated tumors had a median overall survival of 9.6 [IQR: 3.7-16.1] months (HR 1.08, 95% CI 0.55-2.12; p = 0.82).

In patients receiving at least one line of systemic therapy (n = 67), the median overall survival for the group of patients without detectable molecular alterations (n = 46) was 13.65 months [IQR: 6.4-20.0] (Fig. 4). In the KRAS mutant subgroup, the median overall survival of patients receiving systemic treatment (n = 15) was 10.3 [IQR: 3.7-16.8] months (HR: 1.08, 95% CI 0.54-2.18; p = 0.80). In patients with EGFR mutant and ALK rearranged tumors treated with TKI (n = 6), the median overall survival was 32.5 [IQR: 19.6 – 38.4] months (HR: 0.27, 95% IC 0.08 – 0.9, p = 0.033).

Discussion

The understanding of the local prevalence of molecular alterations in patients with lung adenocarcinoma is relevant to optimize their cancer care. In this study, around 14% of patients had an actionable EGFR mutation or ALK fusion, rendering further opportunities of treatment with
tyrosine kinase inhibitors. The prevalence of EGFR and ALK mutations in this study was similar to that reported previously in other series from Argentina\textsuperscript{27, 31}. Interestingly, the prevalence of EGFR mutations seems lower compared to other countries in Latin-America\textsuperscript{27}. To our knowledge, this is the first study to report results of KRAS mutations in Argentinean population. The prevalence of KRAS mutations in our population were similar to the reported in Mexico, Colombia, Peru and Brazil and lower compared to TCGA and French cohorts\textsuperscript{27, 29}. The prevalence of \textit{EGFR} mutations and \textit{ALK} rearrangements in our population was similar to that reported in studies from other western countries in Europe and North America\textsuperscript{9, 32}.

The study of targetable molecular drivers allows to optimize patients care by providing personalized cancer therapies. In our study, patients whose tumors harbored

\begin{table}
\centering
\caption{Clinical characteristics of patients with complete molecular analysis}
\begin{tabular}{lcc}
\hline
Characteristics & N° of patients & \\
\hline
Age at diagnosis (median) & 64 [IQR: 57.7 - 71] & \\
Sex & & \\
Men & 46 & 55 \\
Women & 38 & 45 \\
Ethnicity & & \\
Caucasian & 78 & 93 \\
Native American & 5 & 6 \\
Asian & 1 & 1 \\
Disease presentation & & \\
Upfront advanced disease & 54 & 64 \\
Relapsed disease at inclusion & 30 & 36 \\
Smoking habit & & \\
Current & 28 & 33 \\
Former & 40 & 48 \\
Never & 16 & 19 \\
PS ECOG & & \\
0 & 35 & 42 \\
1 & 35 & 42 \\
2 & 14 & 16 \\
Weight loss > 10\% & 15 & 18 \\
Stage at inclusion & & \\
IIIB & 11 & 13 \\
IV & 73 & 87 \\
Number of metastasis sites & & \\
1 & 56 & 67 \\
2 & 19 & 23 \\
3 or more & 9 & 11 \\
Site of metastasis & & \\
Bone & 32 & 38 \\
Lymph nodes & 28 & 33 \\
Lung & 18 & 21 \\
CNS & 17 & 20 \\
Pleura & 13 & 15 \\
Liver & 11 & 13 \\
Adrenal gland & 6 & 7 \\
Kidney & 1 & 1 \\
Peritoneum & 1 & 1 \\
\hline
\end{tabular}
\end{table}

\textit{PS ECOG: Performance status according to the Eastern Cooperative Oncology Group scoring system; CNS: Central nervous system}
Molecular subtypes of lung adenocarcinoma

Most common diagnostic procedures. In this initial study, around 50% of non-surgical biopsies were insufficient for a complete KRAS, EGFR, BRAF and ALK tumor profiling. In addition to these biomarkers, current clinical standard practice requires testing for programmed death-ligand 1 (PD-L1) expression by IHC, and ROS1 fusions by FISH demanding the use of additional tissue. With the use of real-time PCR and next generation sequencing, the required total amount of DNA needed per sample is diminishing, increasing the efficiency of molecular diagnostics. However, PCR and Sanger sequencing remain the available methodology in many laboratories. These observations are relevant to establish the quality and size of tumor samples and to improve multidisciplinary diagnostic strategies in each institution.

Our study has limitations, it is a single institution study from an academic hospital in the city of Buenos Aires, therefore we cannot extrapolate the prevalence of molecular alterations to the entire country. In addition, the small sample and the relative low proportion of patients with EGFR/ALK alterations treated with kinase inhibitors may overestimate the magnitude of the benefit of this strategy in our cohort.
To our knowledge, this study is the first study in our population to report the prevalence of EGFR, KRAS, and BRAF mutations together with ALK translocations, and to study the patient’s characteristics and outcomes according to molecular subtype and therapeutic strategy in our country.

In conclusion, the prevalence of EGFR, KRAS, and BRAF mutations and ALK translocations observed in this single center study is comparable to that reported in western countries. Patients whose tumors harbor EGFR sensitizing mutations and ALK translocation have a longer survival when treated with targeted therapies. The study of multiple genes is feasible and demands optimization of tumor sampling.

Acknowledgements: This study was funded with a research grant from the Nuria Foundation (Spain). The Nuria Foundation was not involved in the study design, performance or publication. We thank Cecilia Capdevila and Ana Juana Jiménez for their technical cooperation, Fernando Poletta for statistical support and Valeria Melia for proofreading of the manuscript.

Conflicts of Interest: None to declare

References


34. Yoshiko H, Mitsudomi T, Morita S, et al. Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small...


---

**LA TAPA**

*Passionaria caerulea, L. 1753*

Sello postal de Argentina, 2009


Flor de *Passiflora caerulea*, L. 1753 (pasionaria azul, flor de la pasión, mbucuruyá, granadilla). La pasionaria es una planta enredadera, nativa de Sudamérica. Crece espontáneamente o cultivada. La flor, por sus características, está asociada a imaginativas leyendas y a la simbología cristiana de la pasión de Jesús: los estilos representan los tres clavos usados para clavarlo, las cinco anteras las cinco heridas; la corola la corona de espinas, los zarcillos el látigo con que fue flagelado, etc. Los frutos se han incorporado a la gastronomía por sus “maravillosos” beneficios, según los que patrocinan su consumo. Hay preparaciones farmacéuticas de venta libre en la forma de extractos, líquidos, comprimidos y jarabes. En estos sedantes “naturales” se combinan los extractos de pasionaria con los de valeriana, tilo, espino (*Crataegus*), sauce, y, en alguno, vitamina B1. El lector interesado encuentra en PubMed, el 7/10/2018: *passion flower*, 659 referencias, y en *passion fruit*, 747. Y hay un misterio en la historia del arte: ¿Quién y cuándo agregó la pasionaria en un cuadro de Joos van Cleve (c. 1485-1540) datado 1530-35. En Europa, en los años 1530-35, no se conocía ni la flor real o en un herbario, ni una descripción escrita o una imagen.

(Michel E. Abrams en: